Sugi Predict

Sugi Predict / Compounds / SCHEMBL12439731

SCHEMBL12439731

SCHEMBL12439731

CC(C)(C)OC(=O)N1CCN(CCn2cc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.50
▸ USP30 Q70CQ3 1/20 0.45
▸ PIK3CD O00329 1/20 0.38
▸ ACKR3 P25106 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ SCD O00767 1/20 0.37
▸ SCD5 Q86SK9 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.37
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ RET P07949 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15726271 0.94 FFAR1 (0.48) FFAR1USP30ACKR3CHRM2CHRM4
SCHEMBL31168261 0.86 FFAR1 (0.51) FFAR1USP30USP2SMN1; SMN2CHRM2
SCHEMBL31168267 0.86 FFAR1 (0.51) FFAR1USP30USP2SMN1; SMN2CHRM2
SCHEMBL31168266 0.86 FFAR1 (0.51) FFAR1USP30USP2SMN1; SMN2CHRM2
SCHEMBL22776955 0.86 USP30 (0.50) FFAR1USP30GPR119DDB1CRBN
SCHEMBL15532119 0.85 FFAR1 (0.50) FFAR1USP30
SCHEMBL15377252 0.83 FFAR1 (0.50) FFAR1USP30USP2SMN1; SMN2SCD
SCHEMBL31496209 0.83 USP30 (0.48) FFAR1USP30PIK3CDPRMT5WDR77
SCHEMBL25248743 0.83 DDB1 (0.45) FFAR1USP30ACKR3CHRM2CHRM1
SCHEMBL12993498 0.82 FFAR1 (0.49) FFAR1USP30SCDSCD5GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 — — EP disclosed
WO-2025019585-A1 KINASE INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-01-23 — — WO disclosed
EP-2531500-B1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2018-01-24 — — EP disclosed
US-20170135994-A9 NAMPT INHIBITORS ABBVIE INC. (US) 2017-05-18 — — US disclosed
US-20170065575-A1 NAMPT INHIBITORS ABBVIE INC (US) 2017-03-09 — — US disclosed
EP-2727920-B1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2016-11-02 — — EP disclosed
US-20160184282-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-30 — — US disclosed
US-20160184281-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-30 — — US disclosed
US-9193723-B2 NAMPT inhibitors ABBVIE INC. (US) 2015-11-24 — — US disclosed
US-9187472-B2 NAMPT inhibitors ABBVIE INC. (US) 2015-11-17 — — US disclosed
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2014-02-06 — — US disclosed
WO-2013170112-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — WO disclosed
US-20130303508-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
US-20130303509-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
US-20130303510-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
US-20130303511-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — US disclosed
WO-2013018733-A1 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF 富士フイルム株式会社 (JP) 2013-02-07 — — WO disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 — — US disclosed
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives MERCK PATENT GMBH (DE) 2012-11-22 — — US disclosed
WO-2011095196-A1 HETARYL-[1,8]NAPHTHYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303508-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20160184282-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20130303511-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20170065575-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20160184281-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20130303510-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20170135994-A9 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885
US-20140038960-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D FFAR1 2973/4885USP30 2415/4885PIK3CD 2336/4885
US-20120295902-A1 Hetaryl-[1,8]naphthyridine derivatives ATP5F1A, ATP5ME, ATP5F1D FFAR1 2973/4885USP30 2415/4885PIK3CD 2336/4885
US-20130303509-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FFAR1 2750/4885USP30 4391/4885PIK3CD 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback